113 related articles for article (PubMed ID: 20197648)
1. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
2. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
3. ADAM10: a new player in breast cancer progression?
Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
5. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.
Woods NK; Padmanabhan J
J Biol Chem; 2013 Oct; 288(42):30114-30124. PubMed ID: 24022491
[TBL] [Abstract][Full Text] [Related]
7. ADAM10 as a target for anti-cancer therapy.
Moss ML; Stoeck A; Yan W; Dempsey PJ
Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
[TBL] [Abstract][Full Text] [Related]
8. Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
Yao W; Zhuo J; Burns DM; Li YL; Qian DQ; Zhang C; He C; Xu M; Shi E; Li Y; Marando CA; Covington MB; Yang G; Liu X; Pan M; Fridman JS; Scherle P; Wasserman ZR; Hollis G; Vaddi K; Yeleswaram S; Newton R; Friedman S; Metcalf B
Bioorg Med Chem Lett; 2008 Jan; 18(1):159-63. PubMed ID: 18036818
[TBL] [Abstract][Full Text] [Related]
9. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.
Wolpert F; Tritschler I; Steinle A; Weller M; Eisele G
Neuro Oncol; 2014 Mar; 16(3):382-91. PubMed ID: 24327582
[TBL] [Abstract][Full Text] [Related]
10. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
11. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
12. Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis.
Flemming S; Burkard N; Renschler M; Vielmuth F; Meir M; Schick MA; Wunder C; Germer CT; Spindler V; Waschke J; Schlegel N
Cardiovasc Res; 2015 Jul; 107(1):32-44. PubMed ID: 25975259
[TBL] [Abstract][Full Text] [Related]
13. Targeting ADAM10 in Cancer and Autoimmunity.
Smith TM; Tharakan A; Martin RK
Front Immunol; 2020; 11():499. PubMed ID: 32265938
[TBL] [Abstract][Full Text] [Related]
14. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.
Eichenauer DA; Simhadri VL; von Strandmann EP; Ludwig A; Matthews V; Reiners KS; von Tresckow B; Saftig P; Rose-John S; Engert A; Hansen HP
Cancer Res; 2007 Jan; 67(1):332-8. PubMed ID: 17210715
[TBL] [Abstract][Full Text] [Related]
15. Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells.
Pupovac A; Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2015 Jan; 93(1):77-85. PubMed ID: 25155463
[TBL] [Abstract][Full Text] [Related]
16. Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
Burns DM; Li YL; Shi E; He C; Xu M; Zhuo J; Zhang C; Qian DQ; Li Y; Wynn R; Covington MB; Katiyar K; Marando CA; Fridman JS; Scherle P; Friedman S; Metcalf B; Yao W
Bioorg Med Chem Lett; 2009 Jul; 19(13):3525-30. PubMed ID: 19457660
[TBL] [Abstract][Full Text] [Related]
17. Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin.
Kouam PN; Rezniczek GA; Adamietz IA; Bühler H
BMC Cancer; 2019 Oct; 19(1):958. PubMed ID: 31619190
[TBL] [Abstract][Full Text] [Related]
18. Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells.
Kim YH; Jung JC
Oncol Rep; 2012 Nov; 28(5):1869-74. PubMed ID: 22923171
[TBL] [Abstract][Full Text] [Related]
19. Induction of RAGE shedding by activation of G protein-coupled receptors.
Metz VV; Kojro E; Rat D; Postina R
PLoS One; 2012; 7(7):e41823. PubMed ID: 22860017
[TBL] [Abstract][Full Text] [Related]
20. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
